{"id":"W2901742569","doi":"10.1038/s41598-018-34978-4","title":"Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Genetics and Neurodevelopmental Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"Mylan; Zynerba Pharmaceuticals; Teva Pharmaceutical Industries","keywords":"Fragile X syndrome; Placebo; Clinical endpoint; Medicine; Adverse effect; Metabotropic glutamate receptor 5; Antagonist; Metabotropic glutamate receptor; Randomized controlled trial; Pediatrics; Internal medicine; Psychiatry; Glutamate receptor; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00403451,0.0009676638,0.002055966,0.0003578983,0.0003112796,0.0005740925,0.0006018557,0.001156291,0.001738391],"category_scores_gemma":[0.002855456,0.0003174322,0.001587953,0.0002926928,0.0006974958,0.0007707601,0.0003385412,0.001702793,0.0002727809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004816424,"about_ca_system_score_gemma":0.0006743769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007324566,"about_ca_topic_score_gemma":0.00135094,"domain_scores_codex":[0.9987269,0.0007599184,0.0001561069,0.0001479475,0.0001080266,0.0001011881],"domain_scores_gemma":[0.9980121,0.0006138642,0.0005695659,0.0001747251,0.0001870698,0.0004427281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8786221,0.01889169,0.005925528,0.001384382,0.003408963,0.0002644138,0.0004278267,0.0004323518,0.01800695,0.0002221984,0.001266014,0.07114743],"study_design_scores_gemma":[0.6400512,0.3228828,0.02811151,0.0001540329,0.002457758,0.000325596,0.0001230461,0.0004982971,0.002828941,0.0001934184,0.00233069,0.00004256346],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928495,0.004251482,0.0003710561,0.0001840364,0.0000811534,0.001021285,0.0007065528,0.00003781723,0.0004970547],"genre_scores_gemma":[0.9910229,0.003859172,0.001243367,0.0002869923,0.0001566563,0.001656422,0.001096253,0.00001439206,0.000663853],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00403451,"threshold_uncertainty_score":0.02133673,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02857976507745276,"score_gpt":0.3058579932962618,"score_spread":0.277278228218809,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}